This randomized controlled trial addresses the question of whether overt type II diabetes mellitus can be prevented in patients with existing impaired glucose tolerance by inhibiting the renin-angiotensin-aldosterone axis. The results suggest that early RAAS blockade can significantly decrease the likelihood of diabetes development in predisposed patients, but that the cumulative risk of cardiovascular outcomes does not change in either group.

Time Required (estimated): 35 minutes
Title: Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events
Citation: New England Journal of Medicine 2010; doi 10.1056/NEJMoa1001121
Date Created: 2010
Revisions: None Indicated
Disclaimers: Novartis Pharma (see page 12 of the article)
Resource Type: Text
Other: Recommended by Paul Bolin, MD
Recommend to a Colleague/Friend

Was this teaching resource valuable? Scroll down and complete our 6-point Transparent Peer Evaluation.

Transparent Peer Review
Your reviews are anonymous

[starratingmulti id=”3″]

To learn more about our 6-point transparent peer review system, click here



You must be logged in to post a comment.




Speak your mind

  • Nephrology On-Demand Plus

    Our full-featured iOS app for the iPhone and iPad. NOD + integrates
    1. kidney education,
    2. training, and
    3. recruitment

    into a streamlined and user-friendly interface.


  • Kidney Konnection

    A newsletter that discusses sophisticated topics in Nephrology for physicians in Internal Medicine.
    Click here to access your complimentary subscription